GeneDx Q3 2026 adjusted net income falls 47% to $8.6 million
WGS•GeneDx’s third-quarter adjusted net income fell 47% year over year to $8.6 million, while revenue rose 5% to $123.1 million. The company maintained its 2026 revenue guidance at $475–$490 million and lowered its exome and genome revenue growth guidance to at least 17%.
1. Quarterly results and guidance
GeneDx reported third-quarter 2026 adjusted net income of $8.6 million, down 47% year over year, and revenue of $123.1 million, up 5%. Exome and genome revenue increased 12% to $110.4 million, while test result volume rose 25% to 32,134. The company maintained its 2026 revenue guidance at $475–$490 million and lowered its exome and genome revenue growth guidance to at least 17%.
2. Testing offerings
GeneDx expanded its genome testing portfolio with long-read whole genome sequencing and launched an online offering intended to broaden access to pediatric exome testing.
